The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...

The FDA has granted accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of disease progression, ...

Type 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The ...

Novo Nordisk (NVO) announced headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. This marks the first ...

Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 ...

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...

In recent years, a group of medications called SGLT2 inhibitors has gained a lot of attention. These drugs were first developed to help lower blood sugar levels. They work in the kidneys by blocking a ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past?

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney disease progression, hospitalization, and death in ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...